Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma
Pulmonary sarcomatoid carcinoma (PSC) is a rare, poorly differentiated, subtype of non-small cell lung carcinoma (NSCLC) and constitutes approximately 0.1% to 0.5% of all lung malignancies. PSC can be divided into five subtypes based on the 2015 World Health Organization (WHO) classification of lung...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-12-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.12.07 |
| _version_ | 1828772938405380096 |
|---|---|
| author | Lei LIU Ruochuan ZANG Peng SONG Shugeng GAO |
| author_facet | Lei LIU Ruochuan ZANG Peng SONG Shugeng GAO |
| author_sort | Lei LIU |
| collection | DOAJ |
| description | Pulmonary sarcomatoid carcinoma (PSC) is a rare, poorly differentiated, subtype of non-small cell lung carcinoma (NSCLC) and constitutes approximately 0.1% to 0.5% of all lung malignancies. PSC can be divided into five subtypes based on the 2015 World Health Organization (WHO) classification of lung tumors: pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. Some imaging characteristics can be found for PSC although no special symptoms. The accurate pathological diagnosis of PSC can be a significant challenge, which depends on pathology and immunohistochemistry. PSC should be managed similar to other NSCLC, surgical resection is the standard management for early stage cases, moreover, multimodal treatment should be considered. However, PSC is insensitive to radiotherapy and chemotherapy, and has high rate of local and metastatic recurrence and poor prognosis. With the development of molecular pathology, targeted therapy and immunotherapy may have broad prospects. |
| first_indexed | 2024-12-11T14:54:03Z |
| format | Article |
| id | doaj.art-f7c5afdab35240169a83f07b481e5a05 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-11T14:54:03Z |
| publishDate | 2018-12-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-f7c5afdab35240169a83f07b481e5a052022-12-22T01:01:22ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872018-12-01211290290610.3779/j.issn.1009-3419.2018.12.07Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid CarcinomaLei LIU0Ruochuan ZANG1Peng SONG2Shugeng GAO3Department of Thoracic Surgery, Nationanl Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Scienses and Peking Union Medical College, Beijing 100021, ChinaDepartment of Thoracic Surgery, Nationanl Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Scienses and Peking Union Medical College, Beijing 100021, ChinaDepartment of Thoracic Surgery, Nationanl Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Scienses and Peking Union Medical College, Beijing 100021, ChinaDepartment of Thoracic Surgery, Nationanl Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Scienses and Peking Union Medical College, Beijing 100021, ChinaPulmonary sarcomatoid carcinoma (PSC) is a rare, poorly differentiated, subtype of non-small cell lung carcinoma (NSCLC) and constitutes approximately 0.1% to 0.5% of all lung malignancies. PSC can be divided into five subtypes based on the 2015 World Health Organization (WHO) classification of lung tumors: pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. Some imaging characteristics can be found for PSC although no special symptoms. The accurate pathological diagnosis of PSC can be a significant challenge, which depends on pathology and immunohistochemistry. PSC should be managed similar to other NSCLC, surgical resection is the standard management for early stage cases, moreover, multimodal treatment should be considered. However, PSC is insensitive to radiotherapy and chemotherapy, and has high rate of local and metastatic recurrence and poor prognosis. With the development of molecular pathology, targeted therapy and immunotherapy may have broad prospects.http://dx.doi.org/10.3779/j.issn.1009-3419.2018.12.07Lung neoplasmsPulmonary sarcomatoid carcinomaDiagnosisTreatmentPrognosis |
| spellingShingle | Lei LIU Ruochuan ZANG Peng SONG Shugeng GAO Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma Chinese Journal of Lung Cancer Lung neoplasms Pulmonary sarcomatoid carcinoma Diagnosis Treatment Prognosis |
| title | Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma |
| title_full | Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma |
| title_fullStr | Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma |
| title_full_unstemmed | Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma |
| title_short | Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma |
| title_sort | current status of diagnosis and treatment of pulmonary sarcomatoid carcinoma |
| topic | Lung neoplasms Pulmonary sarcomatoid carcinoma Diagnosis Treatment Prognosis |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.12.07 |
| work_keys_str_mv | AT leiliu currentstatusofdiagnosisandtreatmentofpulmonarysarcomatoidcarcinoma AT ruochuanzang currentstatusofdiagnosisandtreatmentofpulmonarysarcomatoidcarcinoma AT pengsong currentstatusofdiagnosisandtreatmentofpulmonarysarcomatoidcarcinoma AT shugenggao currentstatusofdiagnosisandtreatmentofpulmonarysarcomatoidcarcinoma |